Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 3/20 | 0.37 |
| ▸ | INPP5B | P32019 | 2/20 | 0.37 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401828 | 0.90 | INPPL1 (0.37) | INPPL1INPP5BINPP5AGGPS1ENPP2 | |
| SCHEMBL6401094 | 0.88 | INPPL1 (0.38) | INPPL1INPP5BINPP5A | |
| SCHEMBL6396083 | 0.87 | DRD2 (0.38) | INPPL1INPP5BINPP5ADRD2DRD1 | |
| SCHEMBL6397501 | 0.85 | AKR1B10 (0.38) | INPPL1INPP5BINPP5ADRD2DRD1 | |
| SCHEMBL6398557 | 0.82 | INPPL1 (0.36) | INPPL1INPP5BINPP5AGGPS1ENPP2 | |
| SCHEMBL6395713 | 0.81 | INPPL1 (0.40) | INPPL1INPP5BINPP5AGGPS1ENPP2 | |
| SCHEMBL6396486 | 0.80 | GGPS1 (0.40) | GGPS1ENPP2DRD2DRD1TAAR1 | |
| SCHEMBL6402974 | 0.77 | MEN1 (0.37) | INPPL1INPP5BINPP5AAKR1B10AKR1B1 | |
| SCHEMBL6400930 | 0.77 | DRD2 (0.38) | INPPL1INPP5BINPP5ADRD2DRD1 | |
| SCHEMBL6401068 | 0.77 | GGPS1 (0.40) | GGPS1ENPP2DRD2DRD1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-6787528-B2 | THERAPY FOR KIDNEY DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-07 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | PEERCE BRIAN E (US) | 2002-09-19 | — | — | US | disclosed |
| US-6355823-B1 | MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885 |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | SLC10A2, SLC34A3, SLC34A1 | INPPL1 85/4885INPP5B 137/4885INPP5A 190/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.